Publications by authors named "Ferrara Roberto"

Claim this Profile
C
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis.
Fabio Salomone, Massimo Di Maio, Angela Viggiano, Luigi Liguori, Carminia Maria Della Corte, Roberto Ferrara, Roberto Bianco

Crit Rev Oncol Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis.
Antonio Nuccio, Fabio Salomone, Alberto Servetto, Biagio Ricciuti, Daniele Marinelli, Roberto Ferrara

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
Martin Reck, Nikolaj Frost, Solange Peters, Bernard A Fox, Roberto Ferrara

Nat Rev Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.
Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico, Roberto Ferrara

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Roberto Ferrara

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis.
Sara Oresti, Fabio Salomone, Antonio Nuccio, Francesca Rita Ogliari, Silvia Teresa Riva, Roberto Ferrara

EClinicalMedicine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Roberto Ferrara

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.
Fabio Salomone, Giorgia Novero, Oriana Ciani, Roberto Ferrara, Alberto Servetto

Oncologist· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question" by Dafni et al.
Daniele Marinelli, Giuseppe Viscardi, Roberto Ferrara, Filippo Tommaso Gallina

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Roberto Ferrara

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparative Study of Paralympic Veterans with Either a Spinal Cord Injury or an Amputation: Implications for Personalized Nutritional Advice.
Ilaria Peluso, Anna Raguzzini, Elisabetta Toti, Gennaro Boccia, Roberto Ferrara

J Funct Morphol Kinesiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1-Overexpressing NSCLC: Overcoming All-Comer Approach and Network Effect to Weather the "Winter" of Cancer Immunotherapy.
Fabio Salomone, Antonio Nuccio, Roberto Ferrara

J Thorac Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robotic Surgery Is a Safe Treatment in Very Elderly Patients with Resectable Lung Cancer.
Pierluigi Novellis, Riccardo Di Fonzo, Edoardo Bottoni, Veronica Maria Giudici, Domenico Pontillo, Roberto Ferrara

J Clin Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors.
Daniela Esposito, Claudia Maria Ascione, Stefania Belli, Fabiana Napolitano, Alberto Servetto, Roberto Ferrara, Roberto Bianco

J Exp Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.
Mario Occhipinti, Martina Imbimbo, Roberto Ferrara, Vittorio Simeon, Giulia Fiscon

Cochrane Database Syst Rev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
Daniele Marinelli, Antonio Nuccio, Alessandro Di Federico, Francesca Ambrosi, Pietro Bertoglio, Roberto Ferrara

J Thorac Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary management of N2 stage III non-small cell lung cancer: opportunities and challenges for radiation oncology.
Hongcheng Zhu, Daniel G Schep, Marta Isolano, Piergiorgio Muriana, Sarayut L Geater, Roberto Ferrara

Transl Lung Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Roberto Ferrara

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlighting recent achievements to advance more effective cancer immunotherapy.
Beatrice Belmonte, Sheila Spada, Paola Allavena, Matteo Benelli, Vincenzo Bronte, Roberto Ferrara

J Exp Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience.
Francesca Rita Ogliari, Alberto Traverso, Simone Barbieri, Marco Montagna, Filippo Chiabrando, Roberto Ferrara

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment.
Chiara Bennati, Roberto Ferrara, Sabina Sangaletti, Stefano Tamberi, Andrea Spadoni

Clin Lung Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481].
Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, Paolo Ambrosini, Lorenzo Lobianco, Roberto Ferrara

Crit Rev Oncol Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis.
Simeone D'Ambrosio, Fabio Salomone, Filippo Vitale, Annarita Avanzo, Angela Viggiano, Roberto Ferrara, Roberto Bianco

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes.
Luca Bertolaccini, Antonino Carmelo Tralongo, Marzia Del Re, Francesco Facchinetti, Roberto Ferrara

Lung Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wearable electrochemical device based on butterfly-like paper-based microfluidics for pH and Na monitoring in sweat.
Luca Fiore, Vincenzo Mazzaracchio, Arianna Antinucci, Roberto Ferrara, Tommaso Sciarra

Mikrochim Acta· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis